Effectiveness of Dabrafenib plus Trametinib during the Treatment of Melanoma Patients with BRAFV600 mutated Brain Metastases
Berking C, Schadendorf D, Weichenthal M, Eigentler T, Schober K, Mohr P, Kiecker F, Loquai C, Debus D, Gutzmer R, Leiter-Stoeppke U (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 80-81
Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Novartis AG
Switzerland (CH)
Elbe Kliniken Stade-Buxtehude
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Johannes Gutenberg-Universität Mainz (JGU)
Germany (DE)
Klinikum Nürnberg
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Novartis AG
Switzerland (CH)
Elbe Kliniken Stade-Buxtehude
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Johannes Gutenberg-Universität Mainz (JGU)
Germany (DE)
Klinikum Nürnberg
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
How to cite
APA:
Berking, C., Schadendorf, D., Weichenthal, M., Eigentler, T., Schober, K., Mohr, P.,... Leiter-Stoeppke, U. (2020). Effectiveness of Dabrafenib plus Trametinib during the Treatment of Melanoma Patients with BRAFV600 mutated Brain Metastases. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 80-81). HOBOKEN: WILEY.
MLA:
Berking, Carola, et al. "Effectiveness of Dabrafenib plus Trametinib during the Treatment of Melanoma Patients with BRAFV600 mutated Brain Metastases." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2020. 80-81.
BibTeX: Download